Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M006287200 on August 30, 2000

J. Biol. Chem., Vol. 275, Issue 47, 36590-36595, November 24, 2000
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/47/36590    most recent
M006287200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Qureshi, S. A.
Right arrow Articles by Zhang, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Qureshi, S. A.
Right arrow Articles by Zhang, B. B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Activation of Insulin Signal Transduction Pathway and Anti-diabetic Activity of Small Molecule Insulin Receptor Activators*

Sajjad A. QureshiDagger §, Victor DingDagger §, Zhihua LiDagger , Deborah SzalkowskiDagger , Dawn E. Biazzo-AshnaultDagger , Dan XieDagger , Richard Saperstein, Edward Brady, Su Huskey||, Xiaolan Shen**, Kun LiuDagger Dagger , Libo XuDagger Dagger , Gino M. Salituro§§, James V. HeckDagger Dagger , David E. MollerDagger , A. Brian JonesDagger Dagger , and Bei B. ZhangDagger ¶¶

From the Departments of Dagger  Molecular Endocrinology,  Pharmacology, || Drug Metabolism, ** Comparative Medicine, §§ Natural Product Drug Discovery, and Dagger Dagger  Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey 07065

We recently described the identification of a non-peptidyl fungal metabolite (L-783,281, compound 1), which induced activation of human insulin receptor (IR) tyrosine kinase and mediated insulin-like effects in cells, as well as decreased blood glucose levels in murine models of Type 2 diabetes (Zhang, B., Salituro, G., Szalkowski, D., Li, Z., Zhang, Y., Royo, I., Vilella, D., Diez, M. T., Pelaez, F., Ruby, C., Kendall, R. L., Mao, X., Griffin, P., Calaycay, J., Zierath, J. R., Heck, J. V., Smith, R. G. & Moller, D. E. (1999) Science 284, 974-977). Here we report the characterization of an active analog (compound 2) with enhanced IR kinase activation potency and selectivity over related receptors (insulin-like growth factor I receptor, epidermal growth factor receptor, and platelet-derived growth factor receptor). The IR activators stimulated tyrosine kinase activity of partially purified native IR and recombinant IR tyrosine kinase domain. Administration of the IR activators to mice was associated with increased IR tyrosine kinase activity in liver. In vivo oral treatment with compound 2 resulted in significant glucose lowering in several rodent models of diabetes. In db/db mice, oral administration of compound 2 elicited significant correction of hyperglycemia. In a streptozotocin-induced diabetic mouse model, compound 2 potentiated the glucose-lowering effect of insulin. In normal rats, compound 2 improved oral glucose tolerance with significant reduction in insulin release following glucose challenge. A structurally related inactive analog (compound 3) was not effective on insulin receptor activation or glucose lowering in db/db mice. Thus, small molecule IR activators exert insulin mimetic and sensitizing effects in cells and in animal models of diabetes. These results have implications for the future development of new therapies for diabetes mellitus.


* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These authors contributed equally to this paper.

¶¶ To whom correspondence and reprint requests should be addressed: R80W250, Merck Research Laboratories, P. O. Box 2000, 126 E. Lincoln Ave., Rahway, NJ 07065. E-mail: bei_zhang@merck.com.


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
R. A. Velliquette, J. E. Friedman, J. Shao, B. B. Zhang, and P. Ernsberger
Therapeutic Actions of an Insulin Receptor Activator and a Novel Peroxisome Proliferator-Activated Receptor {gamma} Agonist in the Spontaneously Hypertensive Obese Rat Model of Metabolic Syndrome X
J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 422 - 430.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Z. Strowski, Z. Li, D. Szalkowski, X. Shen, X.-M. Guan, S. Juttner, D. E. Moller, and B. B. Zhang
Small-Molecule Insulin Mimetic Reduces Hyperglycemia and Obesity in a Nongenetic Mouse Model of Type 2 Diabetes
Endocrinology, November 1, 2004; 145(11): 5259 - 5268.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Li, N. D. Covino, E. G. Stein, J. H. Till, and S. R. Hubbard
Structural and Biochemical Evidence for an Autoinhibitory Role for Tyrosine 984 in the Juxtamembrane Region of the Insulin Receptor
J. Biol. Chem., July 3, 2003; 278(28): 26007 - 26014.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Li, J. F. Youngren, A. Dunaif, I. D. Goldfine, B. A. Maddux, B. B. Zhang, and J. L. Evans
Decreased Insulin Receptor (IR) Autophosphorylation in Fibroblasts from Patients with PCOS: Effects of Serine Kinase Inhibitors and IR Activators
J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4088 - 4093.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. T. Lee
Functional Genomics and Cardiovascular Drug Discovery
Circulation, September 18, 2001; 104(12): 1441 - 1446.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement